The recent findings by Thailand’s Food and Drug Administration (FDA) that certain batches of the Hong Thai herbal inhaler contained excessive microbial contamination have set off a national debate. What began as a technical regulatory announcement quickly evolved into a reputational crisis, raising questions about product safety, brand accountability, and the balance between regulatory transparency and commercial fairness.
Beyond the headlines, the case serves as a valuable study in how Thailand’s regulatory and legal frameworks intersect in the governance of consumer health products. It underscores that compliance is not merely procedural, but also fundamental to business continuity, brand reputation, and consumer trust.
Regulatory Context: Oversight of Herbal and Traditional Products
Under the Herbal Product Act B.E. 2562 (2019) and the Food and Drug Administration Act B.E. 2522 (1979), all herbal inhalants and similar products fall under FDA supervision. Manufacturers must also obtain registration certificates, ensure compliance with Good Manufacturing Practice (GMP) standards, and operate only from FDA-licensed facilities.
In the Hong Thai case, laboratory testing found contamination above permissible microbial thresholds. The FDA accordingly classified the affected lots as “substandard herbal products”, causing panic among users and triggering regulatory measures under Section 55 of the Herbal Product Act. These include administrative penalties, potential license suspension, and mandatory product recalls.
Some commentators criticized the FDA’s public disclosure for putting a popular national brand in disrepute, while others argued that the agency acted within its statutory mandate. They pointed out that Thailand’s product safety framework is rooted in transparency and consumer protection, and the FDA is legally obliged to alert the public when health risks are identified.
Compliance Gaps and Liability Risks
The incident highlights two central weaknesses in compliance management. The first concerns manufacturing oversight, with reports that portions of the production process occurred at unlicensed facilities, suggesting violations of both GMP standards and facility registration requirements. More critically, they reveal weaknesses in internal controls and supply chain governance, areas that regulators increasingly view as indicators of systemic non-compliance.
The second relates to brand accountability. Under Thailand’s Product Liability Act B.E. 2551 (2008), responsibility for defective products extends not only to manufacturers but also to importers and brand owners whose names appear on the label. Liability is strict, meaning that affected consumers do not need to prove negligence, only that the product was defective and caused harm. This framework ensures that brands cannot delegate quality assurance to suppliers or subcontractors, meaning reputational and legal risk flows upward to the brand owner itself.
Consumer Remedies and Dispute Resolution Pathways
For affected consumers, Thai law provides multiple channels of redress, each carrying implications for corporate exposure.
The FDA and the Office of the Consumer Protection Board (OCPB) serve as the first line of response. Consumers may lodge complaints prompting regulatory investigations, product recalls, and, where appropriate, compensation directives. Administrative remedies are often swift and designed to protect public health rather than assign blame.
When administrative action is insufficient, consumers may seek civil compensation under the Product Liability Act, where the burden of proof shifts partly to the producer or distributor. Courts have discretion to award damages for physical injury, financial loss, or emotional distress. In cases involving large groups of affected users, class actions under Thailand’s Civil Procedure Code offer a cost-efficient collective remedy.
For disputes that centre more on recall procedures or settlement logistics than on personal injury, Alternative Dispute Resolution (ADR) mechanisms, such as mediation and arbitration under the Consumer Case Procedure Act B.E. 2551 (2008), provide faster, less adversarial outcomes. The FDA often facilitates these discussions, helping businesses mitigate reputational harm while demonstrating good-faith compliance.
Business Lessons: Compliance as a Strategic Asset
The Hong Thai case underscores that compliance is not a defensive obligation but a strategic function that supports brand value, consumer trust, and long-term competitiveness. For businesses navigating this sector, it illustrates how effective governance, operational discipline, and regulatory foresight can mean the difference between reputational damage and sustainable growth.
Effective compliance begins with integration. Legal, production, and marketing teams must collaborate under a unified framework that ensures consistency at every stage of the product life cycle, from licensing and formulation to packaging and promotional claims. When compliance is embedded into day-to-day operations rather than treated as a final checkpoint, companies may strengthen their ability to adapt to regulatory changes and withstand unexpected scrutiny.
This integration must also extend beyond internal operations. Delegating production or ingredient sourcing does not absolve a brand of responsibility. Under Thai law, brand owners remain strictly liable for non-compliant or defective products, even when issues originate with third-party suppliers. Robust vendor audits, contractual compliance clauses, and transparent documentation are therefore essential.
Still, even the most diligent compliance systems cannot eliminate all risk. What ultimately defines a company’s integrity is how it responds when problems arise. A well-prepared crisis management plan, covering recall logistics, coordination with authorities, and public communication, can contain both legal exposure and reputational fallout. Transparent, proactive engagement with regulators tends to yield better outcomes than defensive posturing, signalling to consumers that the brand acts responsibly even under pressure.
Ultimately, the goal of compliance is about cultivating credibility. In a market where consumers increasingly value health, safety, and ethical sourcing, adherence to FDA and GMP standards has become a hallmark of trust. For herbal product companies eyeing international expansion, strong compliance also unlocks access to certification and cross-border distribution. Those that view compliance as an investment in brand integrity, rather than a cost of doing business, will be best equipped to grow sustainably and maintain public confidence in an era of heightened accountability.The path forward lies in proactive compliance, transparent communication, and constructive engagement with regulators.
Silk Legal provides a range of services for several practice areas. This article is for information only and should not be construed as legal advice or fact. While we try to keep our updates as accurate as possible, there may be changes to laws or other factors. Please feel free to contact us for a free consultation at [email protected].
